3.Drug-eluting stent: where is the way out?
Chinese Medical Journal 2013;126(6):1005-1007
6.Protective Effect of Gingko Biloba Extract on Acute Lung Hemorrhage Induced by Lipopolysaccharide in Newborn Rats
ya-ling, LIU ; dai-cheng, HAN ; chuan-xiong, XIA
Journal of Applied Clinical Pediatrics 1992;0(06):-
Objective To investigate the protective effect of Gingko Biloba extract (GBE) on acute lung hemorrhage induced by Lipopolysaccharide(LPS) in newborn rats. Methods 1. Acute lung hemorrhage models were reproduced by intraperitoneal injection with LPS (5 mg/kg). 2. Thirty two rats were randomly divided into 4 groups,GBE groups (4 mg/kg,8 mg/kg, 16 mg/kg) and LPS group 5 mg/kg. Results In group LPS, extensive lung hemorrhage was observed after 4 hours of injection . TNF - ? iung content was obvious in LPS group. The expression of lung nuclear factor(NF-kB )immunohistochemistry wasobvious. While the parameters were obviously attenuated by GBE before LPS. Conclusion GBE may be useful in the treatment of acute pulmonary inflammatory disease.
7.Adjunctive anti-tachycardia pacing therapy for the patients with acute myocardial infarction during emergency percutaneous coronary intervention.
Ya-ling HAN ; Ming LIANG ; Quan-min JING
Chinese Journal of Cardiology 2005;33(6):551-552
Adult
;
Aged
;
Aged, 80 and over
;
Angioplasty, Balloon, Coronary
;
Emergency Treatment
;
Female
;
Humans
;
Male
;
Middle Aged
;
Tachycardia
;
therapy
9. Exploration into antithrombotic treatment of coronary heart disease and its perspective in China
Medical Journal of Chinese People's Liberation Army 2015;40(4):255-261
Antithrombotic therapy is the cornerstone of the treatment of coronary heart disease. To optimize antithrombotic therapy is one of ongoing efforts made by cardiovascular physicians. The randomized controlled clinical research of high quality in the field of antithrombotic therapy for coronary heart disease is still lacking in our country at present, and it become an important problem to be urgently solved in China. As there are studies with rich research data on antithrombotic therapy for cardiovascular disease domestically, and the differences in the problems involved between eastern and western populations, a preliminary exploration had been done in 2012 in the research center where the author is serving. This paper chiefly reviews the problems of major concern in antithrombotic therapy, our present situation, and treatment strategy based on our experience in clinical research for years.
10. Analysis of the factor in death rate in hospital of patients with st-segment elevation myocardial infarction: An analysis of data from cardiovascular intervention procedures database
Medical Journal of Chinese People's Liberation Army 2015;40(4):262-265
Objective To explore the relationship between symptom-onset-to-balloon time and in-hospital mortality in patients with ST elevation myocardial infarction (STEMI). Methods Since October 2010, all cardiovascular intervention procedures in military hospitals were registered online, including coronary interventions. Data in this study were originated from this registry database. Primary endpoint was in-hospital mortality, and it was stratified by age and infarction location to explore the effects of these factors on the mortality rate. Results 8878 STEMI patients from 92 military medical centers were enrolled in this study. These patients were divided into 3 groups by the length of onset-to-vessel opening time: interval ≤3h (n=2999), interval between 3 and 6h (n=2369), and interval >6h (n=3510). The in-hospital mortality rate in those groups was 2.5%, 2.9% and 3.0%, respectively (P=0.405). In interval ≤3h group, mortality rate in young (<50 years) patients with non-anterior MI was 0.5%, while mortality rate in old (>70 years) patients with anterior MI was as high as 7.4% (P<0.001). ConclusionsIn-hospital mortality rate in STEMI patients is related to onset-to-vessel opening time. Patients with old age or anterior MI are a high-risk cohort.